Webinar – Beyond THC and CBD: Next Cannabinoids in Demand
The hemp industry is racing towards commoditization. This leads producers and breeders to search for new compounds with market demand. This webinar focuses on the near future, when demand for a combination of multiple metabolites will require better genetic tools to identify and control biosynthesis of entire pathways in plants.
References of papers mentioned in the NRGene webinar (Feb 12, 20202)
1. Farha, Maya A., et al. “Uncovering the hidden antibiotic potential of Cannabis.” BioRxiv (2020): 833392.
2. Rogobete, Alexandru Florin, et al. “Cannabis Sativa Revisited-Crosstalk between microRNAs Expression, Inflammation, Oxidative Stress and Endocannabinoid Response System in Critically Ill Patients with Sepsis.” (2019).
3. Livingston, Samuel J., et al. “Cannabis glandular trichomes alter morphology and metabolite content during flower maturation.” The Plant Journal 101.1 (2020): 37-56.
4. Booth, Judith K., and Jörg Bohlmann. “Terpenes in Cannabis sativa – From plant genome to humans.” Plant Science (2019).
5. Berman, Paula, et al. “A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis.” Scientific reports 8.1 (2018): 1-15
6. Citti, Cinzia, et al. “A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ 9-tetrahydrocannabinol: Δ 9-Tetrahydrocannabiphorol.” Scientific Reports 9.1 (2019): 1-13.
7. Avidekel clinical trial : https://www.xn--4dbcyzi5a.com/wp-content/uploads/2019/12/cannabis-treatment-in-dementia-IACM-2019-final-1.pdf
8. Baram, Liran, et al. “The heterogeneity and complexity of Cannabis extracts as antitumor agents.” Oncotarget 10.41 (2019): 4091.
9. Hanuš, Lumír Ondřej, et al. “Phytocannabinoids: a unified critical inventory.” Natural product reports 33.12 (2016): 1357-1392.
10. Special issue on cannabis medicine: Rambam Maimonides Med J 2020;11(1) (e001-e0010)